Biomarker Technology
World's First Brain Area Specific Biomarker.
Treating mental health disorders using data originating deep in the brain.
Simultaneous fMRI and EEG acquisitions
Advanced Statistical Models
Brain area-specific EEG-fMRI-Pattern (EFP) Biomarker
Clinical research has demonstrated that common mental disorders such as post-traumatic stress disorder (PTSD) and depression are associated with activity of specific brain systems. PTSD with the emotional regulation system that includes the amygdala, and depression with the reward system.
Real-time brain activity can be viewed using functional magnetic resonance imaging (fMRI). However, fMRI is expensive, cumbersome, and impractical to use in routine clinical practice. Conversely, electroencephalogram (EEG) is less expensive, portable and easy to operate, however it is only able to capture surface-level brain activity.
To combine the advantages of the two modalities, Professor Talma Hendler, MD, PhD, Professor of Neuroscience and Psychiatry at Tel Aviv University and Director of the Sagol Brain Institute at the Tel Aviv Sourasky Medical Center, and her team developed machine learning models to register fMRI data from specific deep brain regions to EEG. These proprietary EFPs (EEG-fMRI Pattern) digital biomarkers are used in the Prism device.
Prism gathers years of neuroscience research and places it into the hands of mental healthcare providers. Combining innovative software with an affordable FDA-approved EEG headset for neurofeedback makes it is easy to integrate Prism into any clinical practice. Designed for rapid deployment, the team is trained in the morning and patients can be treated the same afternoon.
Resources
-
Watch Prof. Hendler's presentation "Crossing the Bridge from Idea to Biomarker
The National Institute of Mental Health (NIMH), Division of Translational Research convened a virtual workshop where researchers and FDA officials reviewed the state of the science for neurofeedback (NF) intervention for mental disorders. The program highlighted Prof. Talma Hendler, MD, PhD presenting how she and her team developed the innovative amygdala-based EFP biomarker in the research lab, and insights on the journey to FDA clearance and the use of Prism for PTSD for patient care in clinics today.
-
Go to our Knowledge Center to read the published research articles.